CRDL Cardiol Therapeutics Inc - Ordinary Shares - Class A

$CRDL Jefferies $75M ATM: Pros & Cons Positives: ✅ No immediate dilution confirmed. ✅ $75M provides significant financial flexibility. ✅ Could fund FDA approval and commercialization after Phase III. ✅ Cardiol controls when and how many shares are sold. ✅ Can wait for a higher share price to minimize dilution. ✅ Jefferies is a well-established investment bank. ✅ Strengthens Cardiol’s financial position in future negotiations. Negatives: ❌ $75M is substantial relative to CRDL’s market cap. ❌ Potential dilution if shares are issued at low prices. ❌ Possible selling pressure on the stock. ❌ Raises questions about timing, given the cash runway into Q1 2028. ❌ Uncertainty over whether shares will be sold before Phase III results. My take: Slightly negative short term, potentially very positive long term. The key is WHEN Cardiol chooses to issue shares. No immediate $75M raise has been announced.

$CRDL I dont think its fair to judge a company by the share price to be honnest.. Wether its 1-2-3 USD isnt really important if your a l ong term invstor. Since you still looze all your money if they fail. Im not here to sell at 2-3 USD im here for the final result wich is in around 6 months. Even at 3 USD right now , it would go down since we are in the dead money 6 month waiting game. Bio tech stock need some news to maitain a good Pricing. Look at the chart everytime it got a momentum and spiked it always 100 % of the time slowed down to the point it stumbled back to the same original place before the pump. Its been doiing this for all its lifetime, cause there is no point to bring something that has a chance to fail to 10 USD untill the final result is here. Its just pump and dump , but for the long term if its suceeds it theorically suppose to hit the PT where ever the starting point is located 1 to 3 USD is irrelevant Institution know that , and they sellandbuy accordingly.

$CRDL at least its not under 1.0USD ***yet i know a lot of phase II bio tech struggle below 1.0USD check out $ONCY , this stock was at the same levels during phase II, just like many others. Phase 3 and 2027 is where everything might turn into a win if everything goes according to plan (Eisly plan ....)

$CRDL manipulation is normally something everyone cries when the stock dumps hard and while it’s totally possible with low float stocks like this and I doubt that’s what is going on here, however if this company and whoever they might have looking at them are believing that the product is performing better than expected, MMCAP was in a win win situation to sell and owned enough to crumble the SP. the shorts are beating it down now let see if bigger buyers than this last run start to pile in here in the next several months, it’s possible someone behind the scenes is trying to hammer this down intentionally.

$CRDL Institutional investors own approximately 22% to 26% of Cardiol Therapeutics Inc. (NASDAQ/TSX: CRDL), with latest estimates tracking institutional ownership at roughly 25.85% of the company's shares.

$CRDL this will lead to : Traditional share offerings force a company to sell at a steep discount all at once. An ATM allows them to wait for green days to raise funds selectively, protecting the share price from a sudden crash Biotech investors expect pre-revenue companies to raise capital to survive. By choosing an ATM program instead of a sudden, forced dilutive offering, management is signaling that they want to fund their late-stage clinical progress without causing a major shock to the stock price.

$CRDL Still bullish i prefer ATM than an all at offering it will probably run till 3$ like MIST and fade away so im good with this scenario.

$CRDL B. Riley reiterates its BUY rating and $11 price target on $CRDL after a deeper review of the MAVERIC Phase 3 update. Their main takeaway: expanding from 110 to up to 150 patients is a prudent move to protect statistical power, not evidence the drug is failing. The blinded review showed fewer recurrences than expected across both arms. That could mean CardiolRx is performing better than assumed, or that placebo patients are relapsing more slowly. It’s impossible to distinguish while blinded. MAVERIC already reached its original 110-patient target ahead of schedule, with full enrollment targeted by year-end and topline data expected mid-2027. B. Riley notes that the successful RHAPSODY trial also had a lower-than-expected placebo recurrence rate. Cash runway extends into Q1 2028. B. Riley sees the recent selloff as excessive, but the actual Phase 3 results will determine the outcome.

$CRDL personally all games to the side. I think they will come out on top and this will be worth 40 by the end of next year

$CRDL Freefall may have slowed to a drip, but it’s still a “no touch”…and the drip will most likely continue to sub $1, imo. I’ve been preaching to the choir to sell the spikes for over 4 years now. Did anyone listen? This has taken way too long, yet still has a long way to go. However, it now comes with the added risk of major dilution and potential reverse split attached to it. Thanks to that massive shelf, this can extend its life well past that Vasogen debacle. Keep them checks rolling in 10-4. Guess we now know why Dr. Garnett never purchased shares. 🤔

$CRDL Fast - Loos - Capital. you are exceeding all my expectations … YOU are worth every dime you earn for your entertainment –----- Buy at 1.7xx 👌🤣 YOU are MY winner of the week🤣 Just don't mention your prediction from a year ago … 😂 I am in again 20K -- average 1.08 ..... OUT 1.20+ SWING Trade -

$CRDL I think the big boys are selling because they know they have more time for this to go back up. So take profits while you can and buy lower from the big money moving the share prices for their benefit

$CRDL Can we expect a little bit of upward trend until end of 2026 ? Or will this be dead for the weeks to come 🤨 ?

$CRDL at this point I’m holding till the time they say they are dying haha 🤣 if they end up getting great news from research. This will be massive. Hopefully 30-50 dollars for FDA approval.!!????

$CRDL As expected…this would continue free-fall if the 200ma did not hold. Would still not recommend touching this…not even a nibble, until sub $1 or near the level of that larger prior placement. GLTA

$CRDL welcome back to the level the company said they were approached by an outside entity one year ago requesting to invest long term in the company via private placement offering so they wouldn’t be subject to “pump and dump” conditions. Now between 2 weeks from now and about 14 weeks from now we will see who applied pump and dump conditions and took all of your money while more than doubling theirs. Show me where this didn’t happen in weeks to come and I’ll show you where this SP is headed.

$CRDL Did anyone mention this was a “no touch” and was headed for sub $1? WELL, it has arrived. That 75 million ATM only added fuel to get it there quicker, imo. Yet another brilliant move from leadership! Question: Did any of the tutes have prior knowledge of this as well as the trial extension before they started dumping?

$CRDL How $ANVS raised is what i meant in my previous post ill take the ATM approach then all in offering done with like they do it.

$CRDL this drop was little rough wonder what we will drop to with this phase over next few months till next year. All on p3 baby!

$CRDL Read somewhere cannacord put out an update on crdl a few days ago. Anybody know for certain ? Anybody got the link or highlights? Thx